![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, November 17, 2022 3:14:03 PM
POSTED by LARRY SMITH on NOV 17, 2022 • (0)
Overview
This article puts into perspective the importance of a peer reviewed article on the Phase 3 Trial of murcidencel (better known as DCVax-L) that was published today in the Journal of the American Medical Association. This is a landmark event in which independent experts in an exhaustive process (which I will shortly describe) resoundingly validated previously reported clinical study findings. Here is the link to the article. The major findings presented in the JAMA article are consistent with those presented at the New York Academy of Sciences on May 10, 2022 although there is much more supporting information and analysis. The importance is that the article has been peer reviewed by both editors at JAMA and independent peer reviewers who validate that the trial was successful in showing that murcidencel increases survival in both newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM patients). Here is the conclusion of the JAMA article.
“This phase 3, nonrandomized, externally controlled trial found that the addition of DCVax-L to SOC was associated with a clinically meaningful and statistically significant extension of overall survival in both nGBM and rGBM. Treatment with DCVax-L also had an excellent safety profile and noteworthy tails of long-term survival curves.”
This does not assure that regulatory agencies will approve the drug but it should dramatically increase the confidence of analysts and investors that it could gain regulatory approval. Ladies and gentlemen, this is a huge positive.
About JAMA
JAMA is an international peer-reviewed medical journal published 48 times a year by the American Medical Association; it has published continuously since 1883. As judged by impact with health care professionals, it is one of the top four medical journals in the world along with The Lancet, New England Journal of Medicine and The British Medical Journal. JAMA is the most widely circulated general medical journal in the world, with more than 290,000 recipients of the print journal, more than 1.6 million recipients of electronic tables of contents and alerts, and over 38 million annual visits to the journal's website. JAMA's reach includes a social media presence with more than 982,000 followers on Twitter and Facebook and vast international news media exposure.
The Peer Review Process is Exhaustive
JAMA's acceptance rate for articles is 10% of the more than 11,000 annual submissions and 4% of the more than 6,000 research papers received (like that for murcidencel). Selection of an article for publication indicates that JAMA believes that it is a significant medical advance. All research articles submitted to JAMA are first reviewed by an in-house team of expert editors. A high proportion of research papers, are rejected on the basis of in-house assessment alone. If editors wish to proceed with a paper, they then select appropriate independent peer reviewers. A research article is usually peer reviewed by three or more clinical or subject-based experts and one or more statistical reviewers. The peer review process works to improve submitted articles while preventing any overstating of results from reaching physicians and the public.
Peer reviewers make suggestions for improvements, critique the analysis, and provide recommendations to the authors and the editors. Each published JAMA manuscript, then, benefits from hundreds of hours of work by editors, independent physician experts, statistical experts, manuscript editors, illustrators, proofreaders, and production personnel, who work to ensure that every paper meets exacting standards. It is an intensive interaction between the reviewers and the Company. The collective aim is to present the information in the most balanced and informative way. NWBO management has remarked that the peer review process was intense and beneficial in making the article the best that it could be.
Tagged as JAMA peer reviewed article on DCVax-L + Categorized as LinkedIn, Smith On Stocks Blog
Comment
You must be logged in, or you must subscribe to post a comment.
Login »Register »
Free Newsletter »
© 2022, EXPERT FINANCIAL ANALYSIS AND REPORTING | SMITH ON STOCKS + WORDPRESS/AGREGADO | TERMS OF USE
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM